This paper was presented as a part of the session “Physical Activity—Barriers, Facilitators, and Key Outcomes”on June 20th 2025 at
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in
The approval of tirzepatide, the first dual incretin agonist, for the treatment of type 2 diabetes ushered in a “new